Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2005-03-31
2010-11-09
Chen, Stacy B (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S199100, C424S202100
Reexamination Certificate
active
07829102
ABSTRACT:
Chimeric human-bovine respiratory syncytial virus (RSV) are infectious and attenuated in humans and other mammals and useful in vaccine formulations for eliciting an anti-RSV immune response. Also provided are isolated polynucleotide molecules and vectors incorporating a chimeric RSV genome or antigenome which includes a partial or complete human or bovine RSV “background” genome or antigenome combined or integrated with one or more heterologous gene(s) or genome segment(s) of a different RSV strain. Chimeric human-bovine RSV of the invention include a partial or complete “background” RSV genome or antigenome derived from or patterned after a human or bovine RSV strain or subgroup virus combined with one or more heterologous gene(s) or genome segment(s) of a different RSV strain or subgroup virus to form the human-bovine chimeric RSV genome or antigenome.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4800078 (1989-01-01), Prince et al.
patent: 5716821 (1998-02-01), Wertz et al.
patent: 5789229 (1998-08-01), Wertz et al.
patent: 5869036 (1999-02-01), Belshe et al.
patent: 5882651 (1999-03-01), Murphy et al.
patent: 5922326 (1999-07-01), Murphy et al.
patent: 5993824 (1999-11-01), Murphy et al.
patent: 6033886 (2000-03-01), Conzelmann
patent: 6264957 (2001-07-01), Collins
patent: 6689367 (2004-02-01), Collins et al.
patent: 6699476 (2004-03-01), Collins et al.
patent: 6713066 (2004-03-01), Collins et al.
patent: 7465794 (2008-12-01), Collins
patent: 2002/0146433 (2002-10-01), Krempl et al.
patent: 0 440 219 (1991-08-01), None
patent: 0 702 085 (1996-03-01), None
patent: WO-93 14207 (1993-07-01), None
patent: WO-93 21310 (1993-10-01), None
patent: WO-94 17105 (1994-08-01), None
patent: WO-97 06270 (1997-02-01), None
patent: WO-97 11093 (1997-03-01), None
patent: WO 97/12032 (1997-04-01), None
patent: WO-97 12032 (1997-04-01), None
patent: WO-97 20468 (1997-06-01), None
patent: WO-98 02530 (1998-01-01), None
patent: WO-98 43668 (1998-10-01), None
patent: WO-98 53078 (1998-11-01), None
patent: WO-99 02657 (1999-01-01), None
patent: WO-99 15631 (1999-04-01), None
patent: WO-99 24564 (1999-05-01), None
patent: WO-00 61611 (2000-10-01), None
patent: WO-00 61737 (2000-10-01), None
patent: WO-01 04271 (2001-01-01), None
patent: WO-01 04321 (2001-01-01), None
Collins et al. PNAS USA, 1995, 92:11563-11567.
Tang et al. J. Virology, 2001, 75(23):11328-11335.
Ahmadian et al., Expression Of The ORF-2 Protein Of The Human Respiratory Syncytial Virus M2 Gene, EMBO J vol. 19 2681-2689 (2000).
Anderson, Larry J., Antigenic Characterization of Respiratory Syncytial Virus Strains With Monoclonal Antibodies, Journal Infectious Diseases, vol. 151, No. 4, 626-633 (1985).
Atreya et al., The NS1 Protein Of Human Respiratory Syncytial Virus Is A Potent Inhibitor Of Minigenome Transcription And RNA Replication, J. Virol. vol. 72 1452-1461 (1998).
Bailly et al., A Recombinant Human Parainfluenza Virus Type 3 (PIV3) In Which the Nucleocapsid N Protein Has Been Replaced, Journal Virology, vol. 74, No. 7, 3188-3195 (2000).
Baron et al., Rescue of Rinderpest Virus From Cloned cDNA, Journal Virology, vol. 71, No. 2, 1265-1271 (1997).
Belshe et al., Evaluation of Five Temperature-Sensitive Mutants of Respiratory Syncytial virus In Primates, Journal Medical Virology, vol. 3, 101-110 (1978).
Belshe et al., Experimental Respiratory Syncytial Virus Infection of Four Species of Primates, Journal Medical Virology, vol. 1, 157-162 (1977).
Bermingham et al., The M2-2 Protein of Human Respiratory Syncytial Virus, Proc. Natl. Acad. Sci., vol. 96 11259-11264 (1999).
Buchholz, Ursula J., Chimeric Bovine Respiratory Syncytial Virus With Glycoprotein Gene Substitutions, Journal Virology, vol. 74, No. 3, 1187-1199 (2000).
Buchholz, Ursula J., Generation of Bovine Respiratory Syncytial Virus (BRSV) from cDNA, Journal Virology, vol. 73, No. 1, 251-259 (1999).
Bukreyev, Alexander, Interferon Gamma Expressed By A Recombinant Respiratory Syncytial Virus, Proc. Natl. Acad. Sci., vol. 96 2367-2372 (1999).
Bukreyev, Alexander, Recombinant Respiratory Syncytial Virus From Which Entire SH Gene Deleted Grows In Cell Culture, Journal Virology, vol. 71, No. 12, 8973-8982 (1997).
Bukreyev, Alexander, Recovery of Infectious Respiratory Syncytial Virus Expressing An Additional, Foreign Gene, Journal Virology, vol. 70, No. 10, 6634-6641 (1996).
Cahour et al., Growth-Restricted Dengue Virus Mutants Containing Deletions In The 5 Noncoding Region Of The RNA Genome, Virology vol. 207 68-76 (1995).
Cheng et al., Effective Amplification of Long Targets From Cloned Inserts and Human Genomic DNA, Proc. Natl. Acad. Sci. USA, vol. 91, 5695-5699 (1994).
Chin et al., Field Evaluation Of A Respiratory Syncytial Virus Vaccine And A Trivalet Parainfluenza Virus Vaccine In A Pediatric Population, Am. J. Epidemiol. vol. 89 449-463 (1968).
Clements et al., Evaluation of Bovine Cold-Adapted Human, and Wild-Type Human Parainfluenza Type 3 Viruses in Adult Volunteers, J. Clinical Microbiology, vol. 29, 1175-1182 (1991).
Collins et al., Envelope-Associated 22K Protein of Human Respiratory Syncytial Virus, Journal Virology, vol. 54, No. 1, 65-71 (1985).
Collins et al., Evaluation In Chimpanzees of Vaccinia Virus Recombinants That express The Surface, Vaccine vol. 8 164-168 (1990).
Collins et al., Gene Overlap And Site Specific Atenuation Of Transcription, Proc. Natl. Acad. Sci. USA vol. 84 5134-5138 (1987).
Collins et al., Nucleotide Sequences For The Gene Junction Of Human Respiratory Syncytial Virus Reveal, Proc. Natl. Acad. Sci. USA vol. 83 4594-4598 (1986).
Collins et al., Production of Infectious Human Respiratory Syncytial Virus From Cloned cDNA, Pro. Natl. Acad. Sci., vol. 92, 11563-11567 (1995).
Collins et al., Rational Design Of Live Attenuated Recombinant Vaccine Virus For Human Respiratory Syncytial Virus By Reverse Genetics, Adv. Virus Res. vol. 54 423-451 (1999).
Collins et al., Respiratory Syncytial Virus, Fields Virology, 2nd Ed., 1313-1352, (1996).
Collins et al., Support Plasmids and Support Proteins Required for Recovery of Recombinant Respiratory Syncytial Virus, Virology, vol. 259, 251-255 (1999).
Collins et al., Transcription Elongation Of Respiratory Syncytial Virus A Nonsegmented Negative-Strand RNA Virus, Proc. Natl. Acad. Sci. USA vol. 93 81-85 (1996).
Collins et al., Two Open Reading Frames of 22K mRNA of Human Respiratory Syncytial Virus, Journal General Virology, vol. 71, 3015-3020 (1990).
Connors et al., A Cold Passaged Attenuated Strain of Human Respiratory Syncytial Virus Contains Mutations in the F and L Genes, Virology, vol. 208, 478-484 (1995).
Connors et al., Respiratory Syncytial Virus (RSV) F, G, M2 (22K), And N Proteins Each Induce Resistance To RSV Challenge, J. Virol. vol. 65(3) 1634-1637 (1991).
Connors, Mark, Resistance To Respiratory Syncytial Virus (RSV), Journal Virology, vol. 66, No. 2, 1277-1281 (1992).
Conzelmann, Karl-Klaus, Genetic Manipulation of Non-Segmented Negative-Strand RNA Viruses, Journal General Virology, vol. 77, 381-389 (1996).
Conzelmann, Karl-Klaus, Rescue of Synthetic Genomic RNA Analogs of Rabies Virus By Plasmid-Encoded Proteins, Journal Virology, vol. 68, No. 2, 713-719 (1994).
Corsaro et al., Enhancing The Efficiency Of DNA Mediated Gene Transfer In Mammalian Cells, Somatic Cell Genetics vol. 7 603-616 (1981).
Crowe et al., A Comparison In Chimpanzees of Immunogenic Efficacy of Live Attenuated Respiratory Syncytial Virus (RSV), Vaccine, vol. 11, Issue 14, 1395-1404 (1993).
Crowe et al., Satisfactorily Attenuated Protective Mutants Derived From Partially Attenuated Cold Passaged Respiratory Syncytial Virus, Vaccine, vol. 12, No. 8, 691-699 (1994).
Crowe, James E., A Further Attenuated Derivative of Cold-Passaged Temperature-Sensitive Mutant of Human Respiratory Syncytial Virus, Vaccine, vol. 12, No. 9, 783-790 (1994).
Crowe, James E., Acquisition of the ts Phenotype By Chemically Mutagenized Cold Passaged Human Respiratory Syncytial Virus Vaccine, Virus Genes, vol. 13-3, 269-273 (1996).
Delenda, Christophe, Normal Ce
Buchholz Ursula
Collins Peter L.
Krempl Christine D.
Murphy Brian R.
Whitehead Stephen S.
Chen Stacy B
The United States of America as represented by the Department of
Woodcock & Washburn LLP
LandOfFree
Production of attenuated, human-bovine chimeric respiratory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Production of attenuated, human-bovine chimeric respiratory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Production of attenuated, human-bovine chimeric respiratory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4247168